Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

SOUTH SAN FRANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincides with the company's attendance at the 27th Annual JP Morgan Healthcare Conference in San Francisco.

"2008 was an important year for Sunesis, as we have continued to advance the development of voreloxin in both AML and ovarian cancer. We believe voreloxin has the potential to be a first-in-class anti-cancer agent for treating these diseases and potentially other hematologic and solid tumors," said Daniel Swisher, Chief Executive Officer and President of Sunesis. "We completed enrollment of our Phase 2 platinum-resistant ovarian cancer study and both of our ongoing AML studies are enrolling well, with 45 AML patients enrolled in the fourth quarter of 2008 alone. In the first half of 2009, we anticipate reporting additional data from all three of our ongoing voreloxin studies. We remain on track to initiate a pivotal voreloxin study in AML by the end of this year."

Sunesis is providing an update on the progress of its voreloxin clinical trials as follows:

Phase 2 and 1b/2 Studies of Voreloxin in AML

Sunesis is evaluating single agent voreloxin in an ongoing Phase 2 trial, known as REVEAL-1, in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Interim results recently presented at the 50th Annual Meeting of the American Society of Hematology (ASH) show that voreloxin induces complete remissions in these poor risk patients. At ASH, outcome for the 29 patients enrolled and treated with Schedule A, 72 mg/m2 of vo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ... of the revenue and share analysis. , ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier ... Dr. James L. Sherley, director of the Adult Stem ... on an often overlooked and under appreciated unique property ... Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, ... message to congress participants. He gave the address ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... put on by SkyPilot Networks at Hamburger University in Oak ... statements to rally municipal attendees. He said we need to ... a difference. , ,Quinn had some encouraging remarks about keeping ... or economic blockading. He has made this a priority in ...
... .- Merge Healthcare has been informed that its stock ... the time being, but the company does not know how long ... made the determination to continue the listing of Merge's common stock ... the filing of its annual report for the fiscal year ended ...
... With the support of a local equity investor, an early-stage ... and it is intent on marketing its games to major ... Nintnedo . , ,Selling its products to the "big ... Codebase Productions, LLC and its president, Ben Geisler, but ...
Cached Biology Technology:Municipal broadband in Illinois: Where are the standards? 2Municipal broadband in Illinois: Where are the standards? 3Municipal broadband in Illinois: Where are the standards? 4Emerging game developer begins work on prototypes 2
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be ... Acuity Market Intelligence reports that the long anticipated ... Acuity forecasts that intensifying demand for smart phones, ... will drive a global market of 2.5 billion ... 2020.   According to Maxine ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... escape from captivity they could succeed in breeding and ... found. Their research, published in Evolutionary Applications , ... they are considered for commercial farming. "The ... interest to the aquaculture industry and now genetically modified ...
... to getting our ,body clocks, back in sync and now ... discovered a molecule essential to the process. Researchers ... of light on the circadian clocks (commonly known as ,body ... (QSM), which was intrinsically involved in relaying light-information to the ...
... Kenneth Walsh, PhD, FAHA, the Aram V. ... the Whitaker Cardiovascular Institute at Boston University School ... American Heart Association (AHA) Distinguished Scientist. The AHA ... The AHA created a Distinguished Scientist designation in ...
Cached Biology News:First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2Newly discovered molecule essential to resetting 'body clocks' 2BUSM professor selected as American Heart Association Distinguished Scientist 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: